NCT07169617 2026-03-18
Testing the SurVaxM Vaccine for Lung Cancer Prevention
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
Clinical Trials
12 trialsNCT07437963 2026-03-18
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
NCT02339571 2026-03-17
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT07078604 2026-03-12
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT00026312 2026-03-05
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT04144023 2026-03-05
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
Phase 1 Recruiting
NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
NCT02455557 2026-02-25
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
NCT03879694 2026-02-06
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT05421897 2026-01-29
RAPID
Children's Hospital Los Angeles
Phase 1 Active not recruiting